Literature DB >> 16906593

Pulmonary alveolar proteinosis with myeloproliferative syndrome with myelodysplasia: bronchoalveolar lavage reduces white blood cell count.

Seth M Pollack1, Guillermo Gutierrez, Joao Ascensao.   

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare disorder characterized by surfactant component accumulation in the alveolar space. Primary PAP is likely an autoimmune disorder caused by antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF). When an underlying disease causes PAP, this is called secondary PAP. Hematologic malignancies are an important cause of secondary PAP. As the pathogenesis of primary PAP has become more fully understood, improvements in diagnostic and therapeutic approaches have followed. However, when PAP is secondary to an underlying hematologic malignancy, much remains unclear. Here we describe for the first time a patient with hybrid myelodysplastic syndrome/myeloproliferative syndrome and PAP who had a marked decrease in her white blood cell count following a transbronchial biopsy accompanied by bronchoalveolar lavage (BAL). Similar significant decreases in WBC count accompanied clinical improvement following two unilateral BALs. Given that patients with pulmonary alveolar proteinosis frequently have elevated GM-CSF in bronchoalveolar fluid, this observation provides a unique vantage point to understand the pathophysiology of secondary PAP.

Entities:  

Mesh:

Year:  2006        PMID: 16906593     DOI: 10.1002/ajh.20670

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

Review 1.  Myelodysplastic syndromes and autoimmune diseases--case series and review of literature.

Authors:  Omar Al Ustwani; Laurie A Ford; Sheila J N Sait; Anne Marie W Block; Maurice Barcos; Carlos E Vigil; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Julian Ambrus; Meir Wetzler
Journal:  Leuk Res       Date:  2013-05-18       Impact factor: 3.156

Review 2.  GM-CSF Autoantibody-positive Pulmonary Alveolar Proteinosis with Simultaneous Myeloproliferative Neoplasm.

Authors:  Naoto Imoto; Nakashima Harunori; Katsuya Furukawa; Naoyuki Tange; Atsushi Murase; Masaya Hayakawa; Masatoshi Ichihara; Yosuke Iwata; Hiroshi Kosugi
Journal:  Intern Med       Date:  2017-02-15       Impact factor: 1.271

3.  Clinical features of secondary pulmonary alveolar proteinosis associated with myelodysplastic syndrome: Two case reports.

Authors:  Yin Liu; Lu Lu Chen; Yu Ying Qiu; Yong Long Xiao; Hou Rong Cai
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

4.  Chronic myelomonocytic leukemia-associated pulmonary alveolar proteinosis: A case report and review of literature.

Authors:  Can Chen; Xi-Lian Huang; Da-Quan Gao; Yi-Wei Li; Shen-Xian Qian
Journal:  World J Clin Cases       Date:  2021-02-16       Impact factor: 1.337

5.  Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan.

Authors:  Haruyuki Ishii; John F Seymour; Ryushi Tazawa; Yoshikazu Inoue; Naoyuki Uchida; Aya Nishida; Yoshihito Kogure; Takeshi Saraya; Keisuke Tomii; Toshinori Takada; Yuko Itoh; Masayuki Hojo; Toshio Ichiwata; Hajime Goto; Koh Nakata
Journal:  BMC Pulm Med       Date:  2014-03-05       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.